tiprankstipranks
Chugai Pharmaceutical Co Ltd (JP:4519)
:4519
Japanese Market
4519
Chugai Pharmaceutical Co
RESEARCH TOOLSreports
Want to see JP:4519 full AI Analyst Report?

Chugai Pharmaceutical Co (4519) Stock Forecast & Price Target

4 Followers
See the Price Targets and Ratings of:

4519 Analyst Ratings

Moderate Buy
11Ratings
Moderate Buy
7 Buy
4 Hold
0 Sell
Based on 11 analysts giving stock ratings to
Chugai
Pharmaceutical Co
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

4519 Stock 12 Month Forecast

Average Price Target

¥10,322.73
▲(23.64% Upside)
Based on 11 Wall Street analysts offering 12 month price targets for Chugai Pharmaceutical Co in the last 3 months. The average price target is ¥10,322.73 with a high forecast of ¥13,500.00 and a low forecast of ¥8,200.00. The average price target represents a 23.64% change from the last price of ¥8,349.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6405":"¥6,405","8179":"¥8,179","9953":"¥9,953","11727":"¥11,727","13501":"¥13,501"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":13500,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">¥14K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10322.727272727274,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">¥10K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8200,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">¥8K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6405,8179,9953,11727,13501],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8245,8649.23076923077,9053.461538461539,9457.692307692309,9861.923076923076,10266.153846153846,10670.384615384615,11074.615384615385,11478.846153846154,11883.076923076922,12287.307692307691,12691.538461538461,13095.76923076923,{"y":13500,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8245,8404.825174825175,8564.65034965035,8724.475524475525,8884.3006993007,9044.125874125875,9203.95104895105,9363.776223776225,9523.601398601399,9683.426573426574,9843.251748251749,10003.076923076924,10162.902097902099,{"y":10322.727272727274,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8245,8241.538461538461,8238.076923076924,8234.615384615385,8231.153846153846,8227.692307692309,8224.23076923077,8220.76923076923,8217.307692307691,8213.846153846154,8210.384615384615,8206.923076923076,8203.461538461539,{"y":8200,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8154.814,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7470.656,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7110.503,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7211.702,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6406.035,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6579.942,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6925.789,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7930.908,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8243,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8802,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10145,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9000,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8245,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target¥13,500Average Price Target¥10,323Lowest Price Target¥8,200
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Jefferies Analyst forecast on JP:4519
Stephen Barker
Jefferies
Jefferies
¥9,100→¥8,500
Hold
1.81%
Upside
Reiterated
05/12/26
Analysts Offer Insights on Healthcare Companies: Chugai Pharmaceutical Co (Other OTC: CHGCF), Liquidia Technologies (NASDAQ: LQDA) and Health Catalyst (NASDAQ: HCAT)
Citi Analyst forecast on JP:4519
Unknown Analyst
Citi
Not Ranked
Citi
¥13,300→¥13,500
Buy
61.70%
Upside
Reiterated
04/30/26
Chugai Pharmaceutical Co (CHGCF) Receives a Buy from Citi
Goldman Sachs Analyst forecast on JP:4519
Unknown Analyst
Goldman Sachs
Not Ranked
Goldman Sachs
¥8,900→¥8,950
Hold
7.20%
Upside
Reiterated
04/27/26
Goldman Sachs Keeps Their Hold Rating on Chugai Pharmaceutical Co (CHGCF)
Morgan Stanley Analyst forecast on JP:4519
Unknown Analyst
Morgan Stanley
Not Ranked
Morgan Stanley
¥11,750→¥10,700
Buy
28.16%
Upside
Reiterated
04/27/26
Chugai Pharmaceutical Co (CHGCF) Gets a Buy from Morgan Stanley
Nomura Analyst forecast on JP:4519
Unknown Analyst
Nomura
Not Ranked
Nomura
¥8,200
Hold
-1.78%
Downside
Reiterated
04/24/26
Nomura Remains a Hold on Chugai Pharmaceutical Co (CHGCF)
Bernstein Analyst forecast on JP:4519
Miki Sogi
Bernstein
Bernstein
¥9,800
Buy
17.38%
Upside
Reiterated
04/16/26
Chugai Pharmaceutical Co (CHGCF) Gets a Buy from Bernstein
Macquarie Analyst forecast on JP:4519
Unknown Analyst
Macquarie
Not Ranked
Macquarie
¥9,500
Buy
13.79%
Upside
Reiterated
03/23/26
Macquarie Sticks to Its Buy Rating for Chugai Pharmaceutical Co (CHGCF)
Daiwa Analyst forecast on JP:4519
Unknown Analyst
Daiwa
Not Ranked
Daiwa
¥11,000
Buy
31.75%
Upside
Reiterated
03/05/26
Daiwa Keeps Their Buy Rating on Chugai Pharmaceutical Co (CHGCF)
Mizuho Securities Analyst forecast on JP:4519
Unknown Analyst
Mizuho Securities
Not Ranked
Mizuho Securities
¥10,000
Hold
19.77%
Upside
Reiterated
03/04/26
Mizuho Securities Sticks to Its Hold Rating for Chugai Pharmaceutical Co (CHGCF)
SBI Securities Analyst forecast on JP:4519
Unknown Analyst
SBI Securities
Not Ranked
SBI Securities
¥12,700
Buy
52.11%
Upside
Reiterated
03/02/26
SBI Securities Keeps Their Buy Rating on Chugai Pharmaceutical Co (CHGCF)
SMBC Nikko Analyst forecast on JP:4519
Unknown Analyst
SMBC Nikko
Not Ranked
SMBC Nikko
¥9,500→¥10,700
Buy
28.16%
Upside
Reiterated
02/25/26
Chugai Pharmaceutical Co (CHGCF) Receives a Buy from SMBC Nikko
J.P. Morgan Analyst forecast on JP:4519
Seiji Wakao
J.P. Morgan
J.P. Morgan
¥9,500→¥10,700
Buy
28.16%
Upside
Reiterated
02/06/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
UBS Analyst forecast on JP:4519
Unknown Analyst
UBS
Not Ranked
UBS
¥10,500
Buy
25.76%
Upside
Reiterated
01/27/26
UBS Keeps Their Buy Rating on Chugai Pharmaceutical Co (CHGCF)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Jefferies Analyst forecast on JP:4519
Stephen Barker
Jefferies
Jefferies
¥9,100→¥8,500
Hold
1.81%
Upside
Reiterated
05/12/26
Analysts Offer Insights on Healthcare Companies: Chugai Pharmaceutical Co (Other OTC: CHGCF), Liquidia Technologies (NASDAQ: LQDA) and Health Catalyst (NASDAQ: HCAT)
Citi Analyst forecast on JP:4519
Unknown Analyst
Citi
Not Ranked
Citi
¥13,300→¥13,500
Buy
61.70%
Upside
Reiterated
04/30/26
Chugai Pharmaceutical Co (CHGCF) Receives a Buy from Citi
Goldman Sachs Analyst forecast on JP:4519
Unknown Analyst
Goldman Sachs
Not Ranked
Goldman Sachs
¥8,900→¥8,950
Hold
7.20%
Upside
Reiterated
04/27/26
Goldman Sachs Keeps Their Hold Rating on Chugai Pharmaceutical Co (CHGCF)
Morgan Stanley Analyst forecast on JP:4519
Unknown Analyst
Morgan Stanley
Not Ranked
Morgan Stanley
¥11,750→¥10,700
Buy
28.16%
Upside
Reiterated
04/27/26
Chugai Pharmaceutical Co (CHGCF) Gets a Buy from Morgan Stanley
Nomura Analyst forecast on JP:4519
Unknown Analyst
Nomura
Not Ranked
Nomura
¥8,200
Hold
-1.78%
Downside
Reiterated
04/24/26
Nomura Remains a Hold on Chugai Pharmaceutical Co (CHGCF)
Bernstein Analyst forecast on JP:4519
Miki Sogi
Bernstein
Bernstein
¥9,800
Buy
17.38%
Upside
Reiterated
04/16/26
Chugai Pharmaceutical Co (CHGCF) Gets a Buy from Bernstein
Macquarie Analyst forecast on JP:4519
Unknown Analyst
Macquarie
Not Ranked
Macquarie
¥9,500
Buy
13.79%
Upside
Reiterated
03/23/26
Macquarie Sticks to Its Buy Rating for Chugai Pharmaceutical Co (CHGCF)
Daiwa Analyst forecast on JP:4519
Unknown Analyst
Daiwa
Not Ranked
Daiwa
¥11,000
Buy
31.75%
Upside
Reiterated
03/05/26
Daiwa Keeps Their Buy Rating on Chugai Pharmaceutical Co (CHGCF)
Mizuho Securities Analyst forecast on JP:4519
Unknown Analyst
Mizuho Securities
Not Ranked
Mizuho Securities
¥10,000
Hold
19.77%
Upside
Reiterated
03/04/26
Mizuho Securities Sticks to Its Hold Rating for Chugai Pharmaceutical Co (CHGCF)
SBI Securities Analyst forecast on JP:4519
Unknown Analyst
SBI Securities
Not Ranked
SBI Securities
¥12,700
Buy
52.11%
Upside
Reiterated
03/02/26
SBI Securities Keeps Their Buy Rating on Chugai Pharmaceutical Co (CHGCF)
SMBC Nikko Analyst forecast on JP:4519
Unknown Analyst
SMBC Nikko
Not Ranked
SMBC Nikko
¥9,500→¥10,700
Buy
28.16%
Upside
Reiterated
02/25/26
Chugai Pharmaceutical Co (CHGCF) Receives a Buy from SMBC Nikko
J.P. Morgan Analyst forecast on JP:4519
Seiji Wakao
J.P. Morgan
J.P. Morgan
¥9,500→¥10,700
Buy
28.16%
Upside
Reiterated
02/06/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
UBS Analyst forecast on JP:4519
Unknown Analyst
UBS
Not Ranked
UBS
¥10,500
Buy
25.76%
Upside
Reiterated
01/27/26
UBS Keeps Their Buy Rating on Chugai Pharmaceutical Co (CHGCF)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Chugai Pharmaceutical Co

3 Months
xAi Drug Manufacturers - GeneralTipRanks - xAI
Success Rate
2/3 ratings generated profit
67%
Average Return
+10.87%
Copying xAi Drug Manufacturers - General's trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +10.87% per trade.
1 Year
Tony RenMacquarie
Success Rate
4/5 ratings generated profit
80%
Average Return
+4.66%
Copying Tony Ren's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +4.66% per trade.
2 Years
Tony RenMacquarie
Success Rate
4/5 ratings generated profit
80%
Average Return
+6.38%
Copying Tony Ren's trades and holding each position for 2 Years would result in 80.00% of your transactions generating a profit, with an average return of +6.38% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

4519 Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
0
0
0
1
1
Buy
7
9
13
11
7
Hold
1
0
1
6
7
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
8
9
14
18
15
In the current month, 4519 has received 8 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings. 4519 average Analyst price target in the past 3 months is 10,322.73.
Each month's total comprises the sum of three months' worth of ratings.

4519 Financial Forecast

4519 Earnings Forecast

Next quarter’s earnings estimate for 4519 is ¥75.72 with a range of ¥67.32 to ¥80.13. The previous quarter’s EPS was ¥70.13. 4519 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 4519 has Performed in-line its overall industry.
Next quarter’s earnings estimate for 4519 is ¥75.72 with a range of ¥67.32 to ¥80.13. The previous quarter’s EPS was ¥70.13. 4519 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 4519 has Performed in-line its overall industry.

4519 Sales Forecast

Next quarter’s sales forecast for 4519 is ¥342.10B with a range of ¥323.15B to ¥360.30B. The previous quarter’s sales results were ¥321.75B. 4519 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 4519 has Performed in-line its overall industry.
Next quarter’s sales forecast for 4519 is ¥342.10B with a range of ¥323.15B to ¥360.30B. The previous quarter’s sales results were ¥321.75B. 4519 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 4519 has Performed in-line its overall industry.

4519 Stock Forecast FAQ

What is JP:4519’s average 12-month price target, according to analysts?
Based on analyst ratings, Chugai Pharmaceutical Co Ltd’s 12-month average price target is 10,322.73.
    What is JP:4519’s upside potential, based on the analysts’ average price target?
    Chugai Pharmaceutical Co Ltd has 23.64% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Chugai Pharmaceutical Co Ltd a Buy, Sell or Hold?
          Chugai Pharmaceutical Co Ltd has a consensus rating of Moderate Buy, which is based on 7 buy ratings, 4 hold ratings and 0 sell ratings.
            What is Chugai Pharmaceutical Co Ltd’s share price target?
            The average share price target for Chugai Pharmaceutical Co Ltd is 10,322.73. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is ¥13,500.00 ,and the lowest forecast is ¥8,200.00. The average share price target represents 23.64% Increase from the current price of ¥8,349.
              What do analysts say about Chugai Pharmaceutical Co Ltd?
              Chugai Pharmaceutical Co Ltd’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 11 Wall Streets Analysts.
                How can I buy shares of Chugai Pharmaceutical Co Ltd?
                To buy shares of JP:4519, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.